

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/02168 A1

(51) International Patent Classification⁷: **A61M 15/00**,
F16K 15/14, A61M 16/20, F16K 31/126

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BRAITHWAITE,
Philip [GB/GB]; ML Laboratories Plc, 13 Alexandra Way,
Ashchurch Industrial Estate, Tewkesbury GL20 8NB (GB).**

(21) International Application Number: PCT/GB01/02954

(74) Agent: **HARRISON GODDARD FOOTE**; Tower
House, Merrion Way, Leeds LS2 8PA (GB).

(22) International Filing Date: 5 July 2001 (05.07.2001)

(25) Filing Language:

English

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(30) Priority Data:
0016478.0 5 July 2000 (05.07.2000) GB

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

(71) Applicant (for all designated States except US): **INNO-
VATA BIOMED LIMITED [GB/GB]; The Ziggurat,
Grosvenor Road, St. Albans AL1 3HW (GB).**


[Continued on next page]

(54) Title: ACTUATOR COMPRISING MOVEABLE MEMBRANE

(57) Abstract: There is described an actuator comprising an inlet port and an outlet port and a valve member situated between the inlet and outlet ports, the valve member comprising a moveable apertured membrane such that in the open position an aperture in the membrane is coincident with the inlet and outlet ports and in the closed position the aperture is non-coincident with one or both of the inlet and outlet ports. There is also described an inhaler system using the actuator and a method of administering a medicament to a patient using such an inhaler system.



WO 02/02168 A1





patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

ACTUATOR COMPRISING MOVEABLE MEMBRANE

This invention relates to a novel form of valve and to devices comprising the novel valve.

5

More especially the invention relates to an actuator, for example a pressure activated actuator, e.g. a breath actuator, and a medicament delivery device, e.g. an inhalation device, comprising such an actuator.

- 10 It is well established that asthma and other respiratory diseases can be treated with medicaments administered by inhalation. Such medicaments may be administered in the form of a dry powder with the use of a dry powder inhaler (DPI) or in the form of a solution or suspension with the use of a pressurised metered dose inhaler (MDI). A particular problem encountered with MDI's is that considerable coordination is
15 required for the patient to actuate the pressurised aerosol, thus dispensing the medicament, and inhaling at the correct moment. The problem is exacerbated by the fact that many patients being administered such medicaments are often children or the elderly.
- 20 Thus, there has long been a need for a simple but effective breath actuated mechanism which ensures that the patient inhales at the same time as the aerosol canister is actuated for administration of the medicament. This is often achieved by the use of a breath actuated valve situated in the inhaler or as an integral part of the inhaler. Such a valve is described, for example, in International Patent Application
25 No WO 98/41254. The breath actuated valve described therein comprise a flexible tube which is moveable from a closed, kinked, position to an open, unkinked, position. Whilst such a valve is simple and inexpensive to manufacture, it suffers from the disadvantage that, because a solution or suspension of the medicament must pass through the valve tube, it risks becoming blocked with a build up of deposited
30 medicament.

We have now found a novel form of actuator which is especially suitable for use as a breath activated actuator valve in an inhaler eg an MDI. However, the valve actuator does have greater utility and may be adapted for use in numerous settings eg conventionally known oil, gas or water pipes.

5

Thus according to the invention we provide an actuator comprising an inlet port and an outlet port and a valve member situated between the inlet and outlet ports, the valve member comprising a moveable apertured membrane such that in the open position an aperture in the membrane is coincident with the inlet and outlet ports and 10 in the closed position the aperture is non-coincident with one or both of the inlet and outlet ports.

In some actuator mechanisms of the invention it is conceivable that the moveable apertured membrane is mechanically or electromechanically moved. However, in the 15 most preferred embodiment the membrane is moved by the creation of a pressure differential on either side of the membrane. For example, in the case of a breath activated actuator valve, the pressure differential is created by the patient inhaling.

Thus according to a preferred embodiment we provide an actuator mechanism as 20 hereinbefore described wherein the membrane is moveable from the closed to the open position, or vice versa, by the creation of a pressure differential across the membrane between the inlet and the outlet ports.

The actuator mechanism may comprise a membrane situated at one side of an 25 expansion chamber, such that when the pressure differential is applied across the membrane, the membrane is moved from the closed position to the open position. The expansion chamber comprises a first wall and a second wall, the second wall being of greater dimensions eg of greater surface area, than the first wall. The dimensions of the membrane will be such as to be similar to the dimensions of the 30 second wall ie greater than the first wall. Thus, in the closed position a portion of the membrane will lie outside the expansion chamber. In the closed position the

membrane is held substantially against the first wall, such that any apertures in the membrane are held and sealed against the wall. When the membrane moves to the open position, the applications of the pressure differential urges the membrane to move from the first wall and therefore exposing the apertures and allowing flow of material through the inlet and outlet ports via the apertures. If the pressure differential applied is sufficient, then the membrane may be urged to lie substantially against the second wall, in which the apertures will be arranged so as to be coincident with the inlet and outlet ports. Therefore, a portion of the membrane outside the expansion chamber in the closed position, will be drawn into the expansion chamber 10 in the open position.

In the most preferred embodiment the expansion chamber comprises a hemispherical chamber wherein the second wall is hemispherical or arcuate and the first wall is plane wall. The hemispherical wall is provided with an outlet port and the plane wall 15 is provided with an inlet port.

The membrane is anchored at one end and is provided with biasing means at the other end, keeping the membrane taught against the plane wall of the expansion chamber.

20 Thus the pressure differential applied across the membrane preferably provides a greater pressure on the side of the membrane adjacent the plane first wall than that experienced on the side adjacent the arcuate second wall.

25 The pressure differential can be applied by increasing the pressure on the plane first wall side or by decreasing the pressure on the arcuate second wall side. In the case of a breath actuated valve, the pressure differential is created by the patient inhaling, thus decreasing the pressure on the arcuate second wall side of the membrane.

30 As previously mentioned, the actuator mechanism of the invention has utility in a variety of areas. However, it is most suitable for use in a medicament delivery

device, such as an MDI, thus creating a breath actuated MDI. Therefore according to a further feature of the invention we provide a pressure activated metered dose medicament delivery device comprising an actuator mechanism as hereinbefore described.

5

Such a pressure activated metered dose medicament delivery device will comprise a body adapted to retain a medicament dispenser eg in the form of an aerosol canister, and a medicament delivery orifice, the actuator mechanism of the invention will generally be situated between the medicament dispenser and the medicament delivery
10 orifice although other sitings of the actuator mechanism are possible.

In a preferred embodiment, a pressure activated medicament delivery device of the invention comprises a body and a medicament delivery orifice and situated between the body and the orifice is an actuator mechanism as hereinbefore described, but the
15 expansion chamber is remote from the valve mechanism for example, the expansion chamber may be attached to the side of the body.

By the term pressure activated we mean activated by the creation of a pressure differential. Thus, the pressure differential may arise from an increase or a decrease
20 in pressure, e.g. by application of a vacuum, for example, by a patient sucking or inhaling.

According to a preferred aspect of the invention we provide a breath actuated inhaler, e.g. an MDI, comprising a valve mechanism as hereinbefore described.

25

The preferred MDI of the invention comprises a body and a mouthpiece; situated between the body and the mouthpiece is an actuator mechanism as hereinbefore described; an expansion chamber is provided which is remote from the actuator mechanism, for example, at the side of the body.

30

The actuator mechanism may comprise a membrane with a single aperture or a plurality of apertures. When a plurality of apertures is used then a corresponding number of inlet and outlet ports may be present between the medicament dispenser and the mouthpiece. The inlet and outlet ports may take the form of conduits of eg 1-
5 2mm diameter between the medicament dispenser and the mouthpiece. When a plurality of conduits are present, there may be either side of the membrane such that the membrane is sandwiched between the sets of conduits. In such a mechanism the conduits will be aligned whilst the apertures of the membrane are non-coincident with the conduits until the actuator is activated and the membrane apertures are
10 moved to be coincident with the conduits.

The expansion chamber may advantageously be provided with one or more air inlet orifices which aid the creation of a pressure differential at either side of the membrane. The air inlet orifices should be in the planar first wall of the expansion
15 chamber. Any number of air inlet orifices may be included, but we have found that from 1 to 6, e.g. 4, is suitable.

Preferentially, the membrane is anchored at one end and a load attached at the other end. When used in an MDI, the membrane may be anchored adjacent the dispensing
20 conduits and loaded at the other end. However, it is preferred that the membrane is anchored at the distal end of the strip and loaded at the end adjacent to the dispensing conduits.

The mouthpiece of the inhaler may lead directly to the expansion chamber of the
25 actuator mechanism. However, in the preferred embodiment wherein the expansion chamber is situated on the side of the MDI body one or more conduits may lead from the mouthpiece to the expansion chamber.

Many different materials may be used as the membrane in the actuator mechanism.
30 The material may vary depending upon the nature of the material intended to pass through the valve for example, if the actuator mechanism is intended to be used in an

oil pipeline, then it must be non-perishable when in contact with oil. Most importantly it should be a flexible, non-elastic and non-porous material. More particularly when the actuator mechanism is used such it is actuated by a gas pressure differential, as in a breath actuated MDI, then the membrane material should be non-
5 gas permeable. Thus, plastics materials are well suited for use as the membrane material, poly vinyl acetate being one example of such a plastics material.

A variety of medicaments may be administered by using the inhaler of the invention. Such medicaments are generally antibiotics, bronchodilators or other anti-asthma
10 drugs. Such medicaments include, but are not limited to β_2 -agonists, e.g. fenoterol; formoterol, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol and terbutaline; non-selective beta-stimulants such as isoprenaline; xanthine bronchodilators, e.g. theophylline, aminophylline and choline theophyllinate; anticholinergics, e.g. ipratropium bromide; mast cell stabilisers, e.g. sodium cromoglycate and ketotifen;
15 bronchial anti-inflammatory agents, e.g. nedocromil sodium; and steroids, e.g. beclomethasone dipropionate, fluticasone, budesonide and flunisolide; and combinations thereof.

It is within the scope of this invention for two or more medicaments to be
20 administered.

Specific combinations of medicaments which may be mentioned include combinations of steroids, such as, beclomethasone dipropionate, fluticasone, budesonide and flunisolide; and combinations of β_2 -agonists, such as, formoterol
25 and salmeterol. It is also within the scope of this invention to include combinations of one or more of the aforementioned steroids with one or more of the aforementioned β_2 -agonists.

Further medicaments which may be mentioned include systemically active materials,
30 such as, proteinaceous compounds and/or macromolecules, for example, hormones and mediators, such as insulin, human growth hormone, leuprolide and alpha

interferon; growth factors, anticoagulants, immunomodulators, cytokines and nucleic acids.

It is within the scope of this invention to include combinations of any of the
5 aforementioned medicaments.

According to a further aspect of the invention we provide a method of delivering a medicament which comprises the use of a pressure activated medicament delivery device as hereinbefore described.

10

According to a yet further aspect of the invention we provide a method of treatment of a patient suffering from a disorder, e.g. a respiratory disorder or a systemic disorder, such as insulin dependent diabetes which comprises the administration of a therapeutically effective amount of a medicament by the use of a pressure activated
15 medicament delivery device as hereinbefore described.

Thus we especially provide a method as hereinbefore described wherein the disorder is insulin dependant diabetes and the medicament is insulin.

20 The invention will now be described by way of example only and with reference to the accompanying drawings, in which Figure 1 is a perspective drawing of a disassembled valve of the invention;

Figure 2 is an end view of a valve of the invention;

25 Figure 3 is a cross-sectional side view of valve of the invention in the closed position;

Figure 4 is a cross-sectional side view of a valve of the invention in the open position;

Figure 5 is a cross-sectional side view of a metered dose inhaler comprising a
30 valve of the invention;

Figure 6 is a schematic partial representation of a metered dose inhaler comprising a valve of the invention in the closed position; and

Figure 7 is a schematic partial representation of a metered dose inhaler comprising a valve of the invention in the open position.

5

Referring to Figures 1 and 2, an actuator mechanism (1) comprises an inlet port member (2) with an inlet conduit (2a) and an outlet port member (3) with an outlet conduit (3a), and a membrane (4). The inner surface(s) of the inlet port member (2) is substantially planar and the inner surface (6) of the outlet port member (3) is arcuate. The membrane (4) is provided with an anchorage point (7) in the form of an aperture which is adapted to engage with an anchoring point (8) in the form of a protrusion on the inner surface (6) of the outlet port member (3). In order to retain the membrane (4) taut, a biasing weight (9) is attached to the end (10) of the membrane (4) distal to the anchorage point (7). Also, the inner arcuate surface (6) of the outlet port member (3) has a planar surface (11) adjacent the anchoring point (8). A planar surface (12) is also provided at the end of the arcuate surface distal to the anchoring point (8). Thus, when the inlet port member (2) and the outlet port member (3) are brought together, the membrane (4) is held against the inner planar surface (6) of the inlet port (2).

20

Referring to Figures 3 and 4, when the actuator mechanism is the closed position, the membrane (4) is held against the inner planar surface (5) of the inlet port member (2) by the planar portions (11 and 12) of the outlet port member (3).

25

The inlet port member (2) and the outlet port member (3) join together and the inner planar surface (5) and the inner arcuate surface (6) create an expansion chamber (13).

30

The biasing member (9) is attached to the end (10) of the membrane (4) and keeps the membrane (4) taut. When a pressure differential is applied across the membrane (4), for example a lower pressure is exerted on the outlet port (3), leaving a (relatively) higher pressure on inlet port (2), then the film material is urged from the

closed position, to lie against the inner arcuate surface (6) of the outlet port member (3). Since the membrane (4) is anchored around its anchorage point (7), the distal end (10) of the membrane (4) is urged into the expansion chamber (13).

- 5 Referring to Figure 5, a metered dose inhaler (MDI) (14) comprises a body (15), adapted to house a medicament containing aerosol (16), and a mouthpiece (17). The body (15) is provided on one side (18) with an expansion chamber (19) which is connected to the mouthpiece (17) via a conduit (20). The expansion chamber (19) comprises an inner arcuate surface (22) and on the side adjacent to the body (15) it has a planar surface (21). A membrane (23) lies adjacent the planar surface (21) and is anchored about a point (24) between a planar end surface (25) of the arcuate member (26). The membrane (23) is kept taught by squeezing between planar surfaces (27 and 28) and the inner portion of the mouthpiece (17).
- 10
- 15 Referring to Figure 6, the inner end of the mouthpiece (17) is provided with conduits (29) connecting the mouthpiece (17) to the medicament dispensing chamber (30). A membrane (23) is anchored against the planar surface (21) of the expansion chamber (19). Apertures (33) in the membrane are misaligned with the conduits (2a). The conduits (29) are made up of two parts, a first part (31) adjacent to the mouthpiece (17) and a second part (32) adjacent to the medicament dispensing chamber (30). Apertures (33) in the membrane are misaligned with the conduits (29) and the membrane (23) is held taught by being squeezed between the first and second ports (31 and 32) of the conduit member. In this position, the valve mechanism is closed. Although not essential, the expansion chamber (19) is provided with air inlets (34) to facilitate creation of a pressure differential.
- 20
- 25

Referring to Figure 7, when a patient depresses the medicament containing aerosol (16) (not shown) medicament is released, but with the valve in the closed position, no medicament is dispensed. When a patient inhales through the mouthpiece (17) a pressure differential is created across the membrane (23). This is facilitated by the presence of air inlets (33). The membrane (23) is urged against the arcuate surface

(6) of the expansion chamber (19). This causes the distal end (10) of the membrane (23) to be pulled towards the expansion chamber (19). Therefore, the apertures (33) of the membrane (23) are brought into line with the conduits (29) and thus bringing the valve mechanism into the open position and allowing the free flow of
5 medicament.

10

15

20

25

30

35

40 P36139WO

CLAIMS

1. An actuator comprising an inlet port and an outlet port and a valve member situated between the inlet and outlet ports, the valve member comprising a moveable apertured membrane such that in the open position an aperture in the membrane is coincident with the inlet and outlet ports and in the closed position the aperture is non-coincident with one or both of the inlet and outlet ports.
5
2. An actuator according to claim 1 wherein the membrane is moved by the creation of a pressure differential on either side of the membrane.
10
3. An actuator according to claim 2 wherein the pressure differential is created by a patient inhaling.
- 15 4. An actuator according to claim 2 wherein the membrane is moveable from the closed to the open position, or vice versa, by the creation of a pressure differential across the membrane between the inlet and the outlet ports.
5. An actuator according to claim 1 wherein the valve mechanism comprises a
20 membrane situated at one side of an expansion chamber, such that when the pressure differential is applied across the membrane, the membrane is moved from the closed position to the open position.
- 25 6. An actuator according to claim 5 wherein the expansion chamber comprises a first wall and a second wall, the second wall being of greater dimensions than the first wall.
7. An actuator according to claim 1 wherein, in the closed position a portion of the membrane lies outside the expansion chamber.

8. An actuator according to claim 5 wherein the expansion chamber comprises a hemispherical chamber wherein the second wall is hemispherical or arcuate and the first wall is plane wall.
- 5 9. An actuator according to claim 5 wherein the membrane is anchored at one end and is provided with biasing means at the other end, keeping the membrane taut against the plane wall of the expansion chamber.
- 10 10. An actuator according to claim 5 wherein the pressure differential applied across the membrane provides a greater pressure on the side of the membrane adjacent the plane first wall than that experienced on the side adjacent the arcuate second wall.
- 15 11. An actuator according to claim 1 wherein the pressure differential is applied by decreasing the pressure on the arcuate second wall side.
12. A pressure activated medicament delivery device comprising an actuator mechanism according to claim 1
- 20 13. A pressure activated medicament delivery device according to claim 12 comprising a body adapted to retain a medicament dispenser, a medicament delivery orifice and an actuator mechanism according to claim 1.
- 25 14. A pressure activated medicament delivery device according to claim 13 wherein the actuator mechanism is situated between the body and the medicament delivery orifice, and the expansion chamber is remote from the actuator mechanism.
15. A pressure activated medicament delivery device according to claim 14 wherein the expansion chamber may be attached to the side of the body of the device.

16. A pressure activated medicament delivery device according to claim 12 characterised in that the device is an inhaler.
 17. A pressure activated medicament delivery device according to claim 16
5 characterised in that the inhaler is a breath actuated inhaler.
 18. A pressure activated medicament delivery device according to claim 16 characterised in that the inhaler is an MDI.
- 10 19. A pressure activated medicament delivery device according to claim 13 wherein the actuator mechanism comprises a membrane with a plurality of apertures.
- 15 20. A pressure activated medicament delivery device according to claim 19 wherein the number of inlet and outlet ports corresponds to the number of apertures.
21. A pressure activated medicament delivery device according to claim 13 wherein the expansion chamber is provided with one or more air inlet orifices.
22. A pressure activated medicament delivery device according to claim 13
20 wherein the membrane is anchored at the distal end of the strip and loaded at the end adjacent to the dispensing conduits.
23. A pressure activated medicament delivery device according to claim 15 wherein one or more conduits lead from the mouthpiece to the expansion chamber.
- 25 24. A method of delivering a medicament which comprises the use of a pressure activated medicament delivery device according to claim 12.
25. A method of treatment of a patient suffering from a disorder which comprises
30 the administration of a therapeutically effective amount of a medicament by the use of a pressure activated medicament delivery device according to claim 12.

26. A method according to claim 25 characterised in that the disorder is insulin dependant diabetes and the medicament is insulin.

5 27. An actuator or a pressure activated medicament delivery device substantially as described with reference to the accompanying examples and drawings.

10

15

20

25

30

35

40

1/5




Fig. 1

2/5




Fig. 2

3/5




Fig. 3

Fig. 4

4/5




Fig. 5

SUBSTITUTE SHEET (RULE 26)

5/5




Fig. 6




Fig. 7

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/GB 01/02954

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61M15/00 F16K15/14 A61M16/20 F16K31/126

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61M F16K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 00399 A (BARAK SWI ;CAESARIA MED ELECTRONICS LTD (IL)) 3 January 1997 (1997-01-03) abstract; figure 5 page 7, line 8 - line 27 ---	1,2, 4-15, 19-23
X	WO 99 26676 A (MEDICARD LTD ;ROTTENBERG DAN (IL)) 3 June 1999 (1999-06-03) page 12, line 4 - line 10; figure 4AB ---	1
A	EP 0 514 085 A (LINDREW PTY LTD) 19 November 1992 (1992-11-19) the whole document ---	1-4, 11-23
A	US 4 534 343 A (NOWACKI CHRISTOPHER ET AL) 13 August 1985 (1985-08-13) ---	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

15 October 2001

Date of mailing of the international search report

24/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax. (+31-70) 340-3016

Authorized officer

Lakkis, A

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 27

see Rule 6.2a PCT

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Intern	Application No
PCT/GB	01/02954

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9700399	A 03-01-1997	IL 114190 A AU 707529 B2 AU 6941296 A CA 2219499 A1 EP 0830533 A2 WO 9700399 A2 JP 11508346 T US 6182698 B1	17-08-1999 15-07-1999 15-01-1997 03-01-1997 25-03-1998 03-01-1997 21-07-1999 06-02-2001
WO 9926676	A 03-06-1999	WO 9926676 A1 AU 5132498 A AU 6515898 A EP 1045708 A1 EP 1035880 A1 WO 9926677 A1	03-06-1999 15-06-1999 15-06-1999 25-10-2000 20-09-2000 03-06-1999
EP 0514085	A 19-11-1992	AT 154883 T AU 651882 B2 AU 1611492 A CA 2068360 A1 DE 69220618 D1 DE 69220618 T2 DK 514085 T3 EP 0514085 A1 ES 2106829 T3 HK 1001491 A1 JP 6205832 A NZ 242663 A US 5385140 A	15-07-1997 04-08-1994 19-11-1992 15-11-1992 07-08-1997 12-02-1998 16-02-1998 19-11-1992 16-11-1997 19-06-1998 26-07-1994 25-03-1994 31-01-1995
US 4534343	A 13-08-1985	NONE	